Neuropsychological effects of interferon β‐1a in relapsing multiple sclerosis

Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined effects of treatment on neuropsychological (NP) performance. To evaluate the effects of interferon β‐1a (IFNβ‐1a, 30 μg administered intramuscularly once weekly [Avonex]) on cognitive function, a Comprehensive NP Battery was administered at baseline and week 104 to relapsing MS patients in the phase III study, 166 of whom completed both assessments. A Brief NP Battery was also administered at 6‐month intervals. The primary NP outcome measure was 2‐year change on the Comprehensive NP Battery, grouped into domains of information processing and learning/memory (set A), visuospatial abilities and problem solving (set B), and verbal abilities and attention span (set C). NP effects were most pronounced in cognitive domains vulnerable to MS: IFNβ‐1a had a significant beneficial effect on the set A composite, with a favorable trend evident on set B. Secondary outcome analyses revealed significant between‐group differences in slopes for Brief NP Battery performance and time to sustained deterioration in a Paced Auditory Serial Addition Test processing rate, favoring the IFNβ‐1a group. These results support and extend previous observations of significant beneficial effects of IFNβ‐1a for relapsing MS. Ann Neurol 2000;48:885–892

[1]  M Rovaris,et al.  Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[2]  G. Zhao,et al.  Effect of interferon β-1b in MS , 2000, Neurology.

[3]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[4]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[5]  R. Herndon,et al.  A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.

[6]  R. Schiffer,et al.  Neuropsychologic status in multiple sclerosis after treatment with glatiramer. , 1999, Archives of neurology.

[7]  C. Granger,et al.  Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1 , 1999, Journal of Neuroimmunology.

[8]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[9]  J K Udupa,et al.  Correlation of volumetric magnetization transfer imaging with clinical data in MS , 1998, Neurology.

[10]  M Rovaris,et al.  Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis , 1998, Neurology.

[11]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[12]  Jeanelle Sheeder,et al.  Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .

[13]  R. P. Kinkel,et al.  Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis , 1997, Neurology.

[14]  J. Ruutiainen,et al.  The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. , 1997, Brain : a journal of neurology.

[15]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[16]  D. Goldstein,et al.  Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b , 1996, Neurology.

[17]  D. Paty,et al.  Patterns of cognitive impairment in relapsing–remitting multiple sclerosis and their relationship to neuropathology on magnetic resonance images. , 1996 .

[18]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[19]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[20]  B. Weinstock-Guttman,et al.  A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients , 1995 .

[21]  L. Amaducci,et al.  Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. , 1995, Archives of neurology.

[22]  Stephen M. Rao,et al.  What Do We Really Know About Cognitive Dysfunction, Affective Disorders, and Stress in Multiple Sclerosis? A Practitioner's Guide , 1994 .

[23]  P. Matthews,et al.  Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.

[24]  M. Hirsch,et al.  Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial , 1993, Annals of neurology.

[25]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[26]  R. Knobler,et al.  Neuropsychological and structural brain lesions in multiple sclerosis , 1992, Neurology.

[27]  E. Miller,et al.  Computerized and conventional neuropsychological assessment of HIV‐1‐infected homosexual men , 1991, Neurology.

[28]  Stephen M. Rao,et al.  Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.

[29]  A. Jennekens‐Schinkel,et al.  Cognition in patients with multiple sclerosis After four years , 1990, Journal of the Neurological Sciences.

[30]  D. Goodkin,et al.  Clinical and demographic predictors of cognitive performance in multiple sclerosis. Do diagnostic type, disease duration, and disability matter? , 1990, Archives of neurology.

[31]  V. Haughton,et al.  Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis , 1989, Neurology.

[32]  A. V. Zomeren,et al.  Cognitive impairment in patients with multiple sclerosis and mild physical disability. , 1987, Archives of neurology.

[33]  R. Heaton,et al.  Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. , 1985, Journal of consulting and clinical psychology.

[34]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[35]  N. Butters,et al.  A preliminary study of the problem-solving strategies of detoxified long-term alcoholics. , 1982, Drug and alcohol dependence.

[36]  D. Gronwall.  Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion , 1977, Perceptual and motor skills.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  F. Floyd,et al.  Factor analysis in the development and refinement of clinical assessment instruments. , 1995 .

[39]  R. McGhee,et al.  Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. , 1992, The Journal of neuropsychiatry and clinical neurosciences.

[40]  E. Kaplan,et al.  Guidelines for neuropsychological research in multiple sclerosis. , 1990, Archives of neurology.

[41]  D. Wechsler.  Manual for the Wechsler Adult Intelligence Scale. , 1955 .